Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov 30;18(4):621-626.
doi: 10.9758/cpn.2020.18.4.621.

Effectiveness and Tolerability of Korean Red Ginseng Augmentation in Major Depressive Disorder Patients with Difficult-to-treat in Routine Practice

Kyung Ho Lee  1 , Won-Myong Bahk  2 , Soo-Jung Lee  2 , Chi-Un Pae  2   3
Affiliations

Effectiveness and Tolerability of Korean Red Ginseng Augmentation in Major Depressive Disorder Patients with Difficult-to-treat in Routine Practice

Kyung Ho Lee et al. Clin Psychopharmacol Neurosci. .

Abstract

Objective: : To test clinical effectiveness and tolerability of Korean Red Ginseng augmentation (RGA) in major depressive disorder (MDD) patients with difficult-to-treat.

Methods: Thirty six patients were enrolled in this 6 weeks, prospective, clinical trial. Rating scales were MontgomeryÅsberg Depression Rating Scale (MADRS), Patient Health Questionnaire-15, Clinical Global Impression-improvement (CGI-I), and Patient Satisfaction Score. The primary endpoint was a remission rate measured by MADRS score at the end of study (≤ 10). Clinical outcomes and tolerability were assessed at baseline, week 2, and week 6.

Results: Among 36 patients, 26 patients completed the study and 28 patients had post-baseline visit data. The remission rate by MADRS score was 39.3% (11/28) and 57.1% by CGI-I scores of 1 or 2 at the end of the study. The mean change of MADRS score was significantly decreased by 44.4% from baseline to the end of study. The most frequent adverse events were headache (7/28, 25.0%) during the study.

Conclusion: Our study indicates the putative effectiveness and tolerability of RGA for treating MDD with difficult-to-treat in clinical practice. However, adequately powered, randomized, controlled trials will be needed to confirm these results.

Keywords: Antidepressants; Depressive disorder; Difficult-to-treat.; Red ginseng; Therapeutics.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest

No potential conflict of interest relevant to this article was reported.

References

    1. Han C, Wang SM, Bahk WM, Lee SJ, Patkar AA, Masand PS, et al. A pharmacogenomic-based antidepressant treatment for patients with major depressive disorder: results from an 8-week, randomized, single-blinded clinical trial. Clin Psychopharmacol Neurosci. 2018;16:469–480. doi: 10.9758/cpn.2018.16.4.469. - DOI - PMC - PubMed
    1. Serretti A. The present and future of precision medicine in psychiatry: focus on clinical psychopharmacology of antide-pressants. Clin Psychopharmacol Neurosci. 2018;16:1–6. doi: 10.9758/cpn.2018.16.1.1. - DOI - PMC - PubMed
    1. Gaynes BN, Warden D, Trivedi MH, Wisniewski SR, Fava M, Rush AJ. What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. Psychiatr Serv. 2009;60:1439–1445. doi: 10.1176/ps.2009.60.11.1439. - DOI - PubMed
    1. Fabbri C, Serretti A. Genetics of treatment outcomes in major depressive disorder: present and future. Clin Psychopharmacol Neurosci. 2020;18:1–9. doi: 10.9758/cpn.2020.18.1.1. - DOI - PMC - PubMed
    1. Rush AJ. STAR*D: what have we learned? Am J Psychiatry. 2007;164:201–204. doi: 10.1176/ajp.2007.164.2.201. - DOI - PubMed